Delving into the Latest Updates on Alpha-Tocopheryloxyacetic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

α-TEA, ALPHA-TEA

Target-

Mechanism

Apoptosis stimulants, Immunostimulants

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

LymphomaSarcomaUterine Cervical Cancer

Inactive Indication

Hormone refractory breast cancerMetastatic human epidermal growth factor 2 positive carcinoma of breast

Originator Organization

Veana Therapeutics, Inc.

Active Organization

Veana Therapeutics, Inc.

Inactive Organization

Veana Therapeutics LLC

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC31H52O4

InChIKeyLCFWOFKPFDWYLR-CEFNRUSXSA-N

CAS Registry261929-52-6

This phase I trial studies the side effects and best dose of alpha-TEA when given together with trastuzumab and to see how well they work for the treatment of HER2+ breast cancer that does not respond to treatment (refractory) and has spread to other places in the body (metastatic). Anti-cancer treatment, such as alpha-TEA, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Alpha-TEA may also alter cancer growth by stimulating the body's immune response against the tumor. Trastuzumab is a form of "targeted therapy" because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Giving alpha-TEA and trastuzumab may work better for the treatment of HER2+ refractory and metastatic breast cancer compared to usual treatment.

Start Date08 Apr 2020

Sponsor / Collaborator

Veana Therapeutics LLC

[+1]

NCT02192346 / CompletedPhase 1IIT

Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer

The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood.
Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.

Start Date04 Aug 2014

Sponsor / Collaborator

Providence Health & Services

100 Clinical Results associated with Alpha-Tocopheryloxyacetic acid

Login to view more data

100 Translational Medicine associated with Alpha-Tocopheryloxyacetic acid

Login to view more data

100 Patents (Medical) associated with Alpha-Tocopheryloxyacetic acid

Login to view more data

224

Literatures (Medical) associated with Alpha-Tocopheryloxyacetic acid

01 Oct 2024·JOURNAL OF DERMATOLOGY

Skin colonization by Staphylococcus aureus in hemodialysis patients with pruritus and the effect of Staphylococcus aureus‐secreted α‐toxin on filaggrin expression

Article

Author: Wu, Cheng‐Ching ; Chang, Long‐Sen ; Chen, Ying‐Jung ; Tsai, Yen‐Yu

Abstract:

Staphylococcus aureus (S. aureus) commonly reside on human skin in residents in long‐term care facilities, yet its colonization and impact on the skin of hemodialysis (HD) patients have yet to be studied. The aim of the present study was to investigate the colonization of S. aureus on the skin of pruritic and non‐pruritic HD patients, and the influence of S. aureus and S. aureus‐secreted α‐toxin on skin barrier function‐related protein expression. In this study, a higher relative S. aureus count in pruritic HD patients compared to non‐pruritic HD patients and healthy subjects were revealed by real‐time polymerase chain reaction. S. aureus and α‐toxin decreased mRNA and protein expression levels of aryl hydrocarbon receptor (AHR), ovo‐like transcriptional repressor 1 (OVOL1), and filaggrin (FLG) in keratinocytes. In addition, anti‐alpha‐hemolysin (anti‐hla) was used as an α‐toxin neutralizer, and it successfully abrogated S. aureus‐induced AHR, OVOL1, and FLG mRNA and protein expression downregulation. Mechanistically, α‐toxin could decrease FLG activity by preventing the recruitment of AHR to the FLG promoter region. In conclusion, pruritic HD patients had higher S. aureus colonization, with S. aureus‐secreted α‐toxin suppressing FLG expression through the AHR‐FLG axis.

01 Aug 2024·FREE RADICAL BIOLOGY AND MEDICINE

Deciphering the enigma of the function of alpha-tocopherol as a vitamin

Article

Author: Traber, Maret G

α-Tocopherol (α-T) is a vitamin, but the reasons for the α-T requirement are controversial. Given that α-T deficiency was first identified in embryos, we studied to the premier model of vertebrate embryo development, the zebrafish embryo. We developed an α-T-deficient diet for zebrafish and used fish consuming this diet to produce α-T deficient (E-) embryos. We showed that α-T deficiency causes increased lipid peroxidation, leading to metabolic dysregulation that impacts both biochemical and morphological changes at very early stages in development. These changes occur at an early developmental window, which takes place prior to an analogous time to when a human knows she is pregnant. We found that α-T limits the chain reaction of lipid peroxidation and protects metabolic pathways and integrated gene expression networks that control embryonic development. Importantly, not only is α-T critical during early development, but the neurodevelopmental process is highly dependent on α-T trafficking by the α-T transfer protein (TTPa). Data from both gene expression and evaluation of the metabolome in E- embryos suggest that the activity of the mechanistic Target of Rapamycin (mTOR) signaling pathway is dysregulated-mTOR is a master regulatory mechanism, which controls both metabolism and neurodevelopment. Our findings suggest that TTPa is needed not only for regulation of plasma α-T in adults but is a key regulator during embryogenesis.

01 May 2024·Biological trace element research

Co-administration of L-Ascorbic Acid and α-Tocopherol Alleviates Arsenic-Induced Immunotoxicities in the Thymus and Spleen by Dwindling Oxidative Stress-Induced Inflammation

Article

Author: Pal, Priyankar ; Pal, Ranjana ; Mukhopadhyay, Prabir Kumar ; Maity, Jeet

Herein, we investigated whether L-ascorbic acid (L-AA) and α-tocopherol (α-T) co-administration has the potential to alleviate arsenic-induced immunotoxicities in the thymus, spleen, and circulating leukocytes. Forty-eight adult male Wistar rats were randomly divided into four groups before the treatment: group I (control); group II (sodium arsenite, 3 mg/kg/day/rat); group III (sodium arsenite + L-AA (200 mg/kg/day/rat) and α-T (400 mg/kg/day/rat)); group IV (L-AA and α-T). The result showed that sodium arsenite exposure (consecutive 30 days) caused weight reduction, structural alterations in the thymus and spleen, accompanied by a decrease in thymocyte and splenocyte count. Decreased superoxide dismutase and catalase activity, increased malondialdehyde and protein-carbonyl content, reduced Nrf2 and Bcl2 expression, and increased p-ERK, NF-kβ, Bax, and cleaved-caspase-3 expression were also observed in the thymus and spleen of arsenic-exposed rats. Enhanced plasma ACTH and corticosterone, ROS-induced apoptosis of lymphocytes were also observed. L-AA and α-T co-administration has the potential to abrogate the deleterious impact of arsenic on the thymus, spleen, and circulating lymphocytes. Whole transcriptome analysis of leukocytes revealed that arsenic treatment augmented the expression of Itga4, Itgam, and MMP9 genes, which might help in transient migration of the leukocytes through the endothelial cell layer. Co-administration with L-AA and α-T maintained Itga4, Itgam, and MMP9 gene expression within leukocytes at a lower level.

1

News (Medical) associated with Alpha-Tocopheryloxyacetic acid

27 Sep 2024

·www.biospace.com

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5, 2024. Dr. Aleena Banerji, M.D., Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Allergy and Immunology Unit at Massachusetts General Hospital, will present information on ALPHA-SOLAR, a long-term open-label trial of navenibart (STAR-0215) in people living with HAE, in an encore presentation of a poster titled “Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215.” The poster session will take place on Friday, October 4 at 6:00pm CEST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the University of Texas Health Science Center at Dallas, will present results from the Phase 1b/2 trial of navenibart (STAR-0215) in an encore presentation of a poster titled “ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes.” The presentation will take place during a session titled “Emerging Treatment Options” on Saturday, October 5 at 9:30am CEST. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn. Contacts Astria Contact: Investor Relations and Media: Elizabeth Higgins investors@astriatx.com

Clinical Study

100 Deals associated with Alpha-Tocopheryloxyacetic acid

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hormone refractory breast cancer	Phase 1	US	Veana Therapeutics LLC	08 Apr 2020
Metastatic human epidermal growth factor 2 positive carcinoma of breast	Phase 1	US	Veana Therapeutics LLC	08 Apr 2020
Lymphoma	Phase 1	-	Veana Therapeutics, Inc.	-
Sarcoma	Phase 1	-	Veana Therapeutics, Inc.	-
Uterine Cervical Cancer	Phase 1	-	Veana Therapeutics, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02192346 (P8, SITC2016)	Phase 1	Advanced cancer	12	Alpha-tocopheryloxyacetic acid (Î±-TEA) 2.4 mg/kg	euyopaadpz(bkapxrpqsy) = 6 developed atrial fibrillation (AF) after starting Î±-TEA dwbliswxpn (appqkfblzx ) View more	Positive	08 Dec 2016
NCT02192346 (P8, SITC2016)	Phase 1	Advanced cancer	12	Alpha-tocopheryloxyacetic acid (Î±-TEA) 4.8 mg/kg		Positive	08 Dec 2016
NCT02192346 (SITC2015)	Phase 1	Advanced cancer CD8 effector memory \| CD38 \| HLA-DR	-	Alpha-tocopheryloxyacetic acid (α-TEA) 4.8mg/kg	ygbvqpmnbl(wtmwwpgera) = xvdzefivbu bhybwgevrw (xggeyjsuzi )	Positive	04 Nov 2015